ストックスクリーナーアプリを入手
549.37
3.73%
19.89
前日終値:
$529.48
開ける：
$534.96
24時間の取引高:
143.08K
Relative Volume:
0.44
時価総額：
$12.67B
収益：
$1.13B
当期純損益:
$-309.44M
株価収益率:
-42.92
EPS:
-12.8001
ネットキャッシュフロー:
$-275.41M
1週間 パフォーマンス:
+2.29%
1か月 パフォーマンス:
+12.78%
6か月 パフォーマンス:
-2.12%
1年 パフォーマンス:
+89.93%
1日の値動き範囲:
$529.80
$554.00
1週間の範囲:
$507.60
$554.00
52週間の値動き範囲:
$285.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
名前
Madrigal Pharmaceuticals Inc
セクター
電話
404-380-9263
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
549.45 | 12.18B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-28 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-06-28 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-04-22 | 開始されました | BofA Securities | Underperform |
| 2024-03-15 | アップグレード | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-02-26 | ダウングレード | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 繰り返されました | Oppenheimer | Outperform |
| 2022-12-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-19 | 繰り返されました | Piper Sandler | Overweight |
| 2022-12-19 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-11-24 | 再開されました | Evercore ISI | Outperform |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-05 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-01-30 | 開始されました | Canaccord Genuity | Buy |
| 2020-01-09 | アップグレード | UBS | Neutral → Buy |
| 2019-11-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-06-10 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-12-12 | 開始されました | B. Riley FBR | Neutral |
| 2018-11-19 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 開始されました | Citigroup | Buy |
| 2018-08-06 | ダウングレード | Goldman | Buy → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Mkt Perform |
すべてを表示
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal gives seven new employees stock awards to join the company - Stock Titan
MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz
Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard
Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900 - Moomoo
Price to earnings forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) added to Russell 1000 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS: MDGL) added to Russell 1000 Index - marketscreener.com
Price to sales forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
(MDGL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MDGL) - TradingView
MDGL Forecast — Price Target — Prediction for 2027 - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating at $900 By Investing.com - Investing.com Canada
MDGL PE Ratio & Valuation, Is MDGL Overvalued - Intellectia AI
Madrigal Pharmaceuticals stock holds at $511.61 as SOLAR Conference event nears, Madrigal Pharmaceuticals - Traders Union
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A Biotech Gem with a 34% Upside Potential - DirectorsTalk Interviews
Madrigal Pharmaceuticals Stockweekly review and NASH sector context - AD HOC NEWS
Madrigal Pharmaceuticals Inc - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Madrigal Shareholders Approve 2026 Equity Compensation Plans - The Globe and Mail
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants - Stock Titan
Madrigal Pharmaceuticals (MDGL) director granted RSUs and stock options - Stock Titan
Madrigal (MDGL) director James Daly granted RSUs and 766-share option - Stock Titan
Madrigal (MDGL) director receives stock grants and 681-share option award - Stock Titan
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards - Stock Titan
Madrigal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LPmoomoo - Moomoo
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes - Investing.com Nigeria
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Madrigal Cooperating With NICE On MASH Drug After Provisional English Funding Rejection - Citeline News & Insights
Price-Driven Insight from (MDGL) for Rule-Based Strategy - Stock Traders Daily
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) 財務データ
収益
当期純利益
現金流量
EPS
2.18%
2.70%
大文字化:
|
ボリューム (24 時間):